Eli Lilly on Wednesday said it will reduce prices for its most commonly prescribed forms of insulin, Humalog and Humulin, by 70% effective from the fourth quarter. Lilly will reduce the price of its non-branded, fast-acting insulin to $25 a vial from May 1. "Aggressive price cuts...should make a real difference for Americans with diabetes," Lilly's CEO David Ricks said.